Lv31
240 积分 2021-05-08 加入
T Cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination With Pembrolizumab in the Phase 1 KEYNOTE-603 Study
1个月前
已完结
Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study
1个月前
已完结
T Cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination With Pembrolizumab in the Phase 1 KEYNOTE-603 Study
2个月前
已完结
Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study
2个月前
已完结
The i3+3 design for phase I clinical trials
4个月前
已完结
An RNA vaccine drives expansion and efficacy of claudin-CAR-T cells against solid tumors
4个月前
已完结
Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy
4个月前
已完结
皖公网安备34019202002308
